Analyst Reco. PolyPid Ltd.

Equities

PYPD

IL0011326795

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 11/02/2026 am IST			5-day change	1st Jan Change
4.680 ^USD	+2.18%		-3.90%	+7.83%

16/12	Polypid names medtech veteran Brooke Story as board chairman	RE
16/12	PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors, Effective December 11, 2025	CI

Analyst Reco.

18/25/18	Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating	MT
05/25/05	Roth Capital Initiates PolyPid at Buy With $9 Price Target	MT
27/24/27	HC Wainwright Adjusts Price Target on PolyPid to $11 From $14, Keeps Buy Rating	MT
12/23/12	HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16	MT
07/22/07	Barclays Downgrades PolyPid to Equalweight From Overweight, Adjusts Price Target to $2.50 From $22	MT
06/22/06	Raymond James Downgrades PolyPid to Outperform From Strong Buy, Adjusts Price Target to $4 From $15	MT
11/22/11	BMO Capital Adjusts PolyPid's Price Target to $25 from $27, Keeps Outperform Rating	MT
14/21/14	POLYPID : JMP Securities Starts PolyPid at Market Outperform With $14 Price Target	MT
30/21/30	POLYPID : Cantor Fitzgerald Starts PolyPid at Overweight With $24 Price Target	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

The best tools reserved for subscribers to boost the performance of your investments!